Back to Search
Start Over
Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma
- Source :
- The Journal of Clinical Investigation, Vol 132, Iss 10 (2022)
- Publication Year :
- 2022
- Publisher :
- American Society for Clinical Investigation, 2022.
-
Abstract
- PRAME is a prominent member of the cancer testis antigen family of proteins, which triggers autologous T cell–mediated immune responses. Integrative genomic analysis in diffuse large B cell lymphoma (DLBCL) uncovered recurrent and highly focal deletions of 22q11.22, including the PRAME gene, which were associated with poor outcome. PRAME-deleted tumors showed cytotoxic T cell immune escape and were associated with cold tumor microenvironments. In addition, PRAME downmodulation was strongly associated with somatic EZH2 Y641 mutations in DLBCL. In turn, PRC2-regulated genes were repressed in isogenic PRAME-KO lymphoma cell lines, and PRAME was found to directly interact with EZH2 as a negative regulator. EZH2 inhibition with EPZ-6438 abrogated these extrinsic and intrinsic effects, leading to PRAME expression and microenvironment restoration in vivo. Our data highlight multiple functions of PRAME during lymphomagenesis and provide a preclinical rationale for synergistic therapies combining epigenetic reprogramming with PRAME-targeted therapies.
- Subjects :
- Hematology
Oncology
Medicine
Subjects
Details
- Language :
- English
- ISSN :
- 15588238
- Volume :
- 132
- Issue :
- 10
- Database :
- Directory of Open Access Journals
- Journal :
- The Journal of Clinical Investigation
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.1a16abd2d3774266828be223d0374b3a
- Document Type :
- article
- Full Text :
- https://doi.org/10.1172/JCI145343